1700034O15Rik Activators
Chemical activators of LLLL and CFNLAS motif containing 1 operate through various molecular interactions that lead to the activation of intracellular signaling pathways, ultimately resulting in the protein's phosphorylation and activation. Forskolin, a direct activator of adenylate cyclase, initiates this cascading effect by elevating cyclic AMP (cAMP) levels, which in turn act as a secondary messenger to activate protein kinase A (PKA). PKA then phosphorylates LLLL and CFNLAS motif containing 1, leading to its functional activation. Similarly, Isoproterenol, a beta-adrenergic agonist, binds to beta-adrenergic receptors and activates Gs proteins, which also stimulate adenylate cyclase, culminating in increased cAMP and subsequent activation of PKA. This process mirrors the activation route initiated by other agonists such as Prostaglandin E2 (PGE2), Histamine, Dopamine, Adenosine, Epinephrine, Salbutamol, and Terbutaline, all of which engage their respective G-protein-coupled receptors to increase adenylate cyclase activity and cAMP levels, leading to PKA-mediated phosphorylation of LLLL and CFNLAS motif containing 1.
In addition to these receptor-mediated mechanisms, certain chemicals inhibit the degradation of cAMP, thereby enhancing its accumulation and further influencing the activity of PKA. For instance, 3-Isobutyl-1-methylxanthine (IBMX) and Rolipram function as inhibitors of phosphodiesterases, the enzymes responsible for cAMP breakdown. By preventing cAMP degradation, these inhibitors sustain elevated levels of this messenger molecule, which persistently activates PKA. Consequently, PKA remains active and continuously phosphorylates LLLL and CFNLAS motif containing 1, maintaining it in an active state. This biochemical relay underscores the intricate nature of cellular signal transduction and exemplifies the diverse mechanisms through which a single protein can be regulated by multiple chemical entities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, binds to beta-adrenergic receptors, causing a conformational change that activates Gs proteins, which in turn activate adenylate cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which may phosphorylate and activate LLLL and CFNLAS motif containing 1. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its G-protein-coupled EP receptors, leading to the activation of adenylate cyclase and an increase in cAMP levels. This activates PKA, which could lead to the phosphorylation and activation of LLLL and CFNLAS motif containing 1. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine interacts with H2 receptors, which are coupled to the adenylate cyclase signaling pathway, leading to an increase in cAMP. This surge in cAMP may activate PKA, which can phosphorylate and activate LLLL and CFNLAS motif containing 1. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can bind to D1-like receptors that are coupled to Gs proteins. Activation of these receptors increases cAMP production, leading to PKA activation. PKA may phosphorylate and subsequently activate LLLL and CFNLAS motif containing 1. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with A2A receptors, which are linked to Gs proteins. This interaction increases adenylate cyclase activity, raising cAMP levels and thereby activating PKA. PKA activation can result in the phosphorylation and activation of LLLL and CFNLAS motif containing 1. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine interacts with beta-adrenergic receptors, which are coupled to Gs proteins, leading to increased adenylate cyclase activity and cAMP levels. The increase in cAMP activates PKA, which may lead to phosphorylation and activation of LLLL and CFNLAS motif containing 1. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels by preventing its degradation. Elevated cAMP activates PKA, which could lead to the phosphorylation and activation of LLLL and CFNLAS motif containing 1. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol is a selective beta2-adrenergic receptor agonist that increases adenylate cyclase activity, boosting cAMP levels, and activating PKA. PKA may then phosphorylate and activate LLLL and CFNLAS motif containing 1. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline acts on beta2-adrenergic receptors, causing an activation of adenylate cyclase, which increases cAMP and activates PKA. This activation of PKA can result in the phosphorylation and subsequent activation of LLLL and CFNLAS motif containing 1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which prevents the breakdown of cAMP, leading to increased levels of this second messenger. The rise in cAMP activates PKA, which can phosphorylate and activate LLLL and CFNLAS motif containing 1. | ||||||